DNA vaccine expressing HIV-1 gp120/immunoglobulin fusion protein enhances cellular immunity

Vaccine

Volumn 28, Issue 31, 2010, Pages 4920-4927

  Shimada, Masaru ^a   Yoshizaki, Shinji ^a   Jounai, Nao ^a   Kondo, Asami ^a   Ichino, Motohide ^a   Ryo, Akihide ^a   Okuda, Kenji ^b  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Fukushimura Hospital   (Japan)

Author keywords

DNA vaccine; HIV; Immunoglobulin

Indexed keywords

DNA VACCINE; DNA VACCINE IMMUNOGLOBULIN GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; HYBRID PROTEIN; IMMUNOGLOBULIN; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EFFECTOR CELL; FEMALE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS LOAD; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; ELECTROPORATION; GENETICS; HIV INFECTIONS; HUMAN; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION;

AIDS VACCINES; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; ELECTROPORATION; FEMALE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; PLASMIDS; RECOMBINANT FUSION PROTEINS; VACCINES, DNA; VIRAL LOAD;

EID: 77954757414     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.05.035     Document Type: Article

References (40)

1. Robinson H.L., Montefiori D.C., Johnson R.P., Manson K.H., Kalish M.L., Lifson J.D., et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 1999, 5(May (5)):526-534.
2. Abe S., Okuda K., Ura T., Kondo A., Yoshida A., Yoshizaki S., et al. Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5. J Gene Med 2009, 11(July (7)):570-579.
3. Someya K., Xin K.Q., Matsuo K., Okuda K., Yamamoto N., Honda M. A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity. J Virol 2004, 78(September (18)):9842-9853.
4. Liu J., O'Brien K.L., Lynch D.M., Simmons N.L., La Porte A., Riggs A.M., et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009, 457(January (7225)):87-91.
5. Roberts D.M., Nanda A., Havenga M.J., Abbink P., Lynch D.M., Ewald B.A., et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006, 441(May (7090)):239-243.
6. Xin K.Q., Jounai N., Someya K., Honma K., Mizuguchi H., Naganawa S., et al. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene Ther 2005, 12(December (24)):1769-1777.
7. Jounai N., Okuda K., Kojima Y., Toda Y., Hamajima K., Ohba K., et al. Contribution of the rev gene to the immunogenicity of DNA vaccines targeting the envelope glycoprotein of HIV. J Gene Med 2003, 5(July (7)):609-617.
8. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001, 292(April (5514)):69-74.
9. Barouch D.H., Craiu A., Kuroda M.J., Schmitz J.E., Zheng X.X., Santra S., et al. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci USA 2000, 97(April (8)):4192-4197.
10. Letvin N.L., Montefiori D.C., Yasutomi Y., Perry H.C., Davies M.E., Lekutis C., et al. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci USA 1997, 94(August (17)):9378-9383.
11. Landolfi N.F. A chimeric IL-2/Ig molecule possesses the functional activity of both proteins. J Immunol 1991, 146(February (3)):915-919.
12. Kurschner C., Ozmen L., Garotta G., Dembic Z. IFN-gamma receptor-Ig fusion proteins. Half-life, immunogenicity, and in vivo activity. J Immunol 1992, 149(December (12)):4096-4100.
13. Barouch D.H., Santra S., Steenbeke T.D., Zheng X.X., Perry H.C., Davies M.E., et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol 1998, 161(August (4)):1875-1882.
14. Ferrone C.R., Perales M.A., Goldberg S.M., Somberg C.J., Hirschhorn-Cymerman D., Gregor P.D., et al. Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains. Clin Cancer Res 2006, 12(September (18)):5511-5519.
15. Jarahian M., Watzl C., Fournier P., Arnold A., Djandji D., Zahedi S., et al. Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. J Virol 2009, 83(August (16)):8108-8121.
16. Arnon T.I., Markel G., Bar-Ilan A., Hanna J., Fima E., Benchetrit F., et al. Harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy. PLoS One 2008, 3(5):e2150.
17. Zheng X.X., Steele A.W., Nickerson P.W., Steurer W., Steiger J., Strom T.B. Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. J Immunol 1995, 154(May (10)):5590-5600.
18. Arthos J., Cicala C., Steenbeke T.D., Chun T.W., Dela Cruz C., Hanback D.B., et al. Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies. J Biol Chem 2002, 277(March (13)):11456-11464.
19. Black R.A., Kronheim S.R., Cantrell M., Deeley M.C., March C.J., Prickett K.S., et al. Generation of biologically active interleukin-1 beta by proteolytic cleavage of the inactive precursor. J Biol Chem 1988, 263(July (19)):9437-9442.
20. Smith D.B., Johnson K.S. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 1988, 67(July (1)):31-40.
21. LaVallie E.R., Rehemtulla A., Racie L.A., DiBlasio E.A., Ferenz C., Grant K.L., et al. Cloning and functional expression of a cDNA encoding the catalytic subunit of bovine enterokinase. J Biol Chem 1993, 268(November (31)):23311-23317.
22. Deliyannis G., Boyle J.S., Brady J.L., Brown L.E., Lew A.M. A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge. Proc Natl Acad Sci USA 2000, 97(June (12)):6676-6680.
23. Niwa H., Yamamura K., Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991, 108(December (2)):193-199.
24. Kojima Y., Xin K.Q., Ooki T., Hamajima K., Oikawa T., Shinoda K., et al. Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine. Vaccine 2002, 20(July (23-24)):2857-2865.
25. Huster K.M., Busch V., Schiemann M., Linkemann K., Kerksiek K.M., Wagner H., et al. Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8+ memory T cell subsets. Proc Natl Acad Sci USA 2004, 101(April (15)):5610-5615.
26. Bachmann M.F., Wolint P., Schwarz K., Jager P., Oxenius A. Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor alpha and CD62L. J Immunol 2005, 175(October (7)):4686-4696.
27. Huster K.M., Koffler M., Stemberger C., Schiemann M., Wagner H., Busch D.H. Unidirectional development of CD8+ central memory T cells into protective Listeria-specific effector memory T cells. Eur J Immunol 2006, 36(June (6)):1453-1464.
28. Lo K.M., Sudo Y., Chen J., Li Y., Lan Y., Kong S.M., et al. High level expression and secretion of Fc-X fusion proteins in mammalian cells. Protein Eng 1998, 11(June (6)):495-500.
29. Craiu A., Barouch D.H., Zheng X.X., Kuroda M.J., Schmitz J.E., Lifton M.A., et al. An IL-2/Ig fusion protein influences CD4+ T lymphocytes in naive and simian immunodeficiency virus-infected Rhesus monkeys. AIDS Res Hum Retroviruses 2001, 17(July (10)):873-886.
30. Barouch D.H., Santra S., Schmitz J.E., Kuroda M.J., Fu T.M., Wagner W., et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000, 290(October (5491)):486-492.
31. Holliger P., Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005, 23(September (9)):1126-1136.
32. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107(June (12)):4781-4789.
33. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008, 8(April (4)):247-258.
34. Saha S., Takeshita F., Sasaki S., Matsuda T., Tanaka T., Tozuka M., et al. Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa. Vaccine 2006, 24(September (37-39)):6240-6249.
35. Seo S.H., Jin H.T., Park S.H., Youn J.I., Sung Y.C. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. Vaccine 2009, 27(September (42)):5906-5912.
36. Livingston B.D., Little S.F., Luxembourg A., Ellefsen B., Hannaman D. Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques. Vaccine 2010, 28(January (4)):1056-1061.
37. Laddy D.J., Yan J., Khan A.S., Andersen H., Cohn A., Greenhouse J., et al. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol 2009, 83(May (9)):4624-4630.
38. Shinoda K., Xin K.Q., Okuda K. A modified HIV challenge assay in mice by using luciferase-expressing vaccinia virus. Vaccine 2006, 24(April (15)):2751-2754.
39. Shimada M., Wang H.B., Kondo A., Xu X.P., Yoshida A., Shinoda K., et al. Effect of therapeutic immunization using Ad5/35 and MVA vectors on SIV infection of rhesus monkeys undergoing antiretroviral therapy. Gene Ther 2009, 16(February (2)):218-228.
40. Wang H.B., Kondo A., Yoshida A., Yoshizaki S., Abe S., Bao L.L., et al. Partial protection against SIV challenge by vaccination of adenovirus and MVA vectors in rhesus monkeys. Gene Ther 2010, 17(January (1)):4-13.